Current Hematologic Malignancy Reports

Papers
(The TQCC of Current Hematologic Malignancy Reports is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions165
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations36
Targeting RUNX1 Germline Variants: Agents Under Investigation27
Monoclonal Gammopathy-Associated Neuropathy26
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease25
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations22
Management of Chronic Myeloid Leukemia in Children and Young Adults22
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities20
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer19
Value in Myeloma Care: Myth or Reality19
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications19
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications19
Allogeneic Transplant for CMML18
Transplantation and Cellular Therapy for Older Adults—The MSK Approach18
Prognostic and Predictive Models in Myelofibrosis16
How Do We Manage Chronic Lymphocytic Leukemia in India15
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications14
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders14
Multiple Myeloma: Current Clinical Landscape and Compounding Costs14
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development13
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia13
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies12
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults12
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia12
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies11
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia10
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders10
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma9
0.029138803482056